GlassScriptPhysician profile
Ali R Tajik
NPI 1629020268
$2,642.46
in general payments reported to CMS, 2019-2025
25 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $546 · 2021: $423 · 2022: $324 · 2023: $452 · 2024: $324 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $570.52 | 2019-2024 | |
| Amgen INC. | $535.66 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $355.34 | 2020-2022 | |
| Pfizer INC. | $215.02 | 2019-2024 | |
| Lilly USA, LLC | $176.11 | 2021-2025 | Jardiance, Zepbound, Emgality |
| Novo Nordisk INC | $75.03 | 2021-2024 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $67.69 | 2019-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $65.84 | 2022-2024 | Verquvo |
| Glaxosmithkline, LLC. | $63.58 | 2019-2020 | |
| Radius Health, INC. | $62.95 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $60.73 | 2024-2025 | |
| Exact Sciences Corporation | $58.71 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $45.31 | 2023-2024 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.97 | 2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $38.55 | 2020-2025 | Airsupra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.33 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $25.42 | 2022 | |
| Abbvie INC. | $25.35 | 2021 | |
| Linus Health, INC. | $25.06 | 2022 | |
| Allergan, INC. | $24.84 | 2020 | |
| Optos, INC. | $18.54 | 2020 | |
| Gilead Sciences, INC. | $18.48 | 2021 | |
| Eisai INC. | $16.30 | 2022 | |
| Bausch Health US, LLC | $13.58 | 2024 | Aplenzin |
| Echosens North America, INC. | $12.55 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Tajik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.